← Back to patent-cliff list
DYP-688
Tier C — Watch / tradeDYP-688
Novartis
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GNAQ, GNA11
Indications (approved)：葡萄膜黑素瘤
Regional status
US
Phase II
2022-07-04
EU
Phase II
2022-07-04
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DYP-688?
Approved indications include: 葡萄膜黑素瘤.
When does the DYP-688 patent expire?
No public expiry year is available for DYP-688 yet; this page updates once verified.
How do I get a quote for DYP-688 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05